Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

NCT Number	NCT06679270
Lead Sponsor	Chiesi Farmaceutici S.p.A.
Conditions	Familial Partial Lipodystrophy
Enrollment	24 participants
Start Date	2024-10-14
Primary Completion	2028-03 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-16